Pathophysiology And Challenges

  • Dengue virus comprises four distinct serotypes.
  • Natural infection confers lifelong homotypic immunity.
  • Heterotypic immunity remains transient.
  • Sub-neutralizing antibodies form complexes with dengue virus.
  • Complexes paradoxically facilitate viral cell entry in host monocytes and macrophages.
  • Phenomenon termed Antibody-Dependent Enhancement increases severe disease risk during secondary heterotypic infection.
  • Vaccine must generate balanced neutralizing immunity against all four serotypes to prevent vaccine-related Antibody-Dependent Enhancement in seronegative individuals.

Licensed Vaccines

Dengvaxia

  • Recombinant live-attenuated tetravalent vaccine.
  • Utilizes yellow fever 17D virus backbone.
  • Administered via three subcutaneous doses at 0, 6, and 12 months.
  • Approved for ages 9-45 years.
  • Pre-vaccination screening mandatory.
  • Indicated strictly for individuals with laboratory-confirmed prior dengue infection.
  • Seronegative recipients face heightened risk of severe dengue hospitalization due to Antibody-Dependent Enhancement.
  • Efficacy remains higher against serotypes 3 and 4.

Qdenga

  • Recombinant live-attenuated tetravalent vaccine.
  • Utilizes dengue serotype 2 backbone.
  • Administered via two subcutaneous doses 3 months apart.
  • Indicated for adults, adolescents, and children older than 4 years.
  • World Health Organization recommends administration for ages 6-16 in high-transmission settings.
  • Sero-independent; pre-vaccination screening unnecessary.
  • Efficacy reaches 80.9% overall and 95.4% against hospitalization at 12 months.
  • Overall efficacy declines to 61.2% over 4.5 years.

Emerging Vaccines

Butantan-DV

  • Live-attenuated chimeric tetravalent vaccine.
  • Utilizes attenuated dengue serotype 4 backbone.
  • Administered as single subcutaneous dose.
  • Approved in Brazil for ages 12-59 years.
  • Sero-independent administration.
  • Demonstrates 80.5% effectiveness against severe dengue over 5 years.
  • Achieves 100% protection against dengue-related hospitalizations.

V181

  • Investigational quadrivalent vaccine currently in Phase 3 trials.
  • Utilizes purified inactivated virus technology.
  • Eliminates vaccine-induced viremia risk.
  • Potentially safe for immunocompromised populations and pregnant women.

Comparative Analysis

FeatureDengvaxiaQdengaButantan-DV
Platform BackboneYellow fever 17DDengue serotype 2Dengue serotype 4
Dosing Schedule3 doses (0, 6, 12 months)2 doses (0, 3 months)Single dose
Target Age9-45 years>4 years12-59 years
Serostatus RequirementStrictly seropositiveSero-independentSero-independent
Administration RouteSubcutaneousSubcutaneousSubcutaneous

Contraindications And Precautions

  • Live-attenuated dengue vaccines contraindicated in immunocompromised individuals.
  • Contraindicated in symptomatic human immunodeficiency virus infection.
  • Contraindicated during pregnancy and lactation.
  • Contraindicated in individuals with severe hypersensitivity to previous doses.